BiotechTube

loteprednol etabonate 0.25% ophthalmic suspension

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Corneal Endothelial Dystrophy

Conditions

Corneal Endothelial Dystrophy, Corneal Edema

Trial Timeline

Nov 23, 2021 → Sep 5, 2023

NCT ID
NCT05136443

About loteprednol etabonate 0.25% ophthalmic suspension

loteprednol etabonate 0.25% ophthalmic suspension is a approved stage product being developed by Kala Pharmaceuticals for Corneal Endothelial Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT05136443. Target conditions include Corneal Endothelial Dystrophy, Corneal Edema.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05136443ApprovedCompleted

Competing Products

12 competing products in Corneal Endothelial Dystrophy

See all competitors
ProductCompanyStageHype Score
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1%AbbViePhase 2
52
0.3% hypromelloseNovartisApproved
85
Mycophenolate Mofetil 2x 1gRocheApproved
85
Subconjunctival afliberceptRegeneron PharmaceuticalsPhase 1
32
riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL systemGlaukosPhase 3
74
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
49
lufepirsen high dose + Vehicle + lufepirsen low doseGlaukosPhase 2
49
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + PlaceboOculis Holding AGPhase 2
47
DT-168Design TherapeuticsPhase 2
47
KPI-012 + KPI-012 VehicleKala PharmaceuticalsPhase 2
44
QR-504aProQRPhase 1
25

Other Products from Kala Pharmaceuticals

KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3
69
KPI-121 1% + Prednisolone acetatePhase 3
69
KPI-121 Ophthalmic Suspension + VehiclePhase 3
69
KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3
69
KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%Phase 3
69